Expertise in
30
conditions

Dr. Joseph F. Mclaughlin

Hematology | Oncology | Internal Medicine
100 Haynes St, 2nd Fl, 
Manchester, CT 
On Staff At
Accepting New Patients
18 Years of Experience
Expertise in
30
conditions
100 Haynes St, 2nd Fl, 
Manchester, CT 

Overview

Joseph Mclaughlin is an Oncologist and an Internal Medicine provider in Manchester, Connecticut. Dr. Mclaughlin has been practicing medicine for over 18 years is highly rated in 30 conditions, according to our data. His top areas of expertise are Lung Cancer, Thrombocytopenia, Gallbladder Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Mclaughlin is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Sidney Kimmell Medical College At Thomas Jefferson University, 2008

Residency

Sidney Kimmell Medical College at Thomas Jefferson University

Specialties

Hematology
Oncology
Internal Medicine

Licenses

Internal Medicine in CT

Board Certifications

American Board Of Internal Medicine, Medical Oncology
American Board Of Internal Medicine, Hematology
American Board Of Internal Medicine

Fellowships

Yale University School of Medicine
Yale University School of Medicine, 2014

Hospital Affiliations

Rockville General Hospital
Manchester Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Nippon Life
  • INSURANCE PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Medical Oncology & Blood Disorders, LLP
100 Haynes St, 2nd Fl, Manchester, CT 06040

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
View 4 Less Clinical Trials

6 Total Publications

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: June 29, 2016
Similar Doctors
Expertise in
7
conditions
Dr. Patrick Mcgann
Hematology | Oncology
Expertise in
7
conditions
Dr. Patrick Mcgann
Hematology | Oncology

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (57.6 miles away)
401-444-5241
Languages Spoken:
English
See accepted insurances

Patrick Mcgann is a Hematologist and an Oncologist in Providence, Rhode Island. Dr. Mcgann is highly rated in 7 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Anemia, Hemolytic Anemia, and Congenital Hemolytic Anemia.

Expertise in
49
conditions
Dr. Todd Alekshun
Hematology | Oncology
Expertise in
49
conditions
Dr. Todd Alekshun
Hematology | Oncology

Hartford Healthcare Medical Group

339 W Main St, 
Avon, CT 
 (17.4 miles away)
860-674-0088
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Todd Alekshun is a Hematologist and an Oncologist in Avon, Connecticut. Dr. Alekshun is highly rated in 49 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Lung Adenocarcinoma.

Expertise in
14
conditions
Dr. Archana Agarwal
Hematology | Oncology
Expertise in
14
conditions
Dr. Archana Agarwal
Hematology | Oncology

Saint Vincent Medical Group-Eaton Place Oncology

1 Eaton Pl Ste 23, 
Worcester, MA 
 (49.9 miles away)
508-363-6515
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Archana Agarwal is a Hematologist and an Oncologist in Worcester, Massachusetts. Dr. Agarwal is highly rated in 14 conditions, according to our data. Her top areas of expertise are Hereditary Pyropoikilocytosis, Hereditary Spherocytosis, Hereditary Elliptocytosis, Hereditary Ovalocytosis, and Splenectomy.

Frequently Asked Questions about Dr. Joseph F. Mclaughlin

How do I make an appointment with Dr. Joseph F. Mclaughlin?

You can book an appointment with Dr. Joseph F. Mclaughlin by calling their office at 860-646-0670. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph F. Mclaughlin a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph F. Mclaughlin is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph F. Mclaughlin specialize in?

While Dr. Joseph F. Mclaughlin is a Hematology, they have specific expertise in Lung Cancer, Thrombocytopenia, and Gallbladder Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Joseph F. Mclaughlin participate in research or clinical trials?

Yes. Dr. Joseph F. Mclaughlin has published 6 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Joseph F. Mclaughlin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph F. Mclaughlin accept my insurance?

Dr. Joseph F. Mclaughlin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 860-646-0670 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mclaughlin's expertise for a condition
ConditionClose
    View All 26 Advanced Conditions
    View All 89 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile